<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996589</url>
  </required_header>
  <id_info>
    <org_study_id>NL76207.091.20</org_study_id>
    <nct_id>NCT04996589</nct_id>
  </id_info>
  <brief_title>Exploring the Potential of Finger Prick Blood for Assessment of BIOmarkers for LOw Grade Inflammation and CVD Risk</brief_title>
  <acronym>BIOLOGIC</acronym>
  <official_title>Exploring the Potential of Finger Prick Blood for Assessment of BIOmarkers for LOw Grade Inflammation and CVD Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wageningen University and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are currently no minimally invasive techniques for the measurement of&#xD;
      lipopolysaccharide (LPS) and Apo-B48 that can be used in samples collected in field settings.&#xD;
      In this project we want to explore whether postprandial assessment of biomarkers LPS and&#xD;
      ApoB48 in blood withdrawn with a finger prick test can be used as marker for low grade&#xD;
      inflammation and risk factor for CVD.&#xD;
&#xD;
      The primary objectives of this pilot study are to a) determine whether postprandial LPS and&#xD;
      ApoB48 levels can be assessed in finger prick blood of both lean subjects and obese subjects;&#xD;
      and b) compare postprandial LPS and ApoB48 levels assessed in venous blood and blood&#xD;
      collected through a finger prick test.&#xD;
&#xD;
      This study is an observational pilot study in which postprandial LPS and ApoB48 will be&#xD;
      assessed before and after ingestion of a high fat load in 5 lean and 5 obese subjects in the&#xD;
      age range 18-70 years.&#xD;
&#xD;
      Samples will be collected under fasting conditions and in response to a high fat challenge&#xD;
      test (1, 2, 4 and 6 hours post ingestion).&#xD;
&#xD;
      The risks for participation are very small if not negligible. No adverse effects of the high&#xD;
      fat challenge were reported previously. Consumption of high amounts of saturated fat may&#xD;
      cause some GI discomfort. Blood sampling will be performed via a cannula and the insertion&#xD;
      can be a painful and may cause a bruise. Finger prick might also give a short pain sensation&#xD;
      and small bruises. The amount of blood that is drawn from participants is relatively small&#xD;
      (total 37.5 ml) and is therefore within acceptable limits. There are no direct benefits for&#xD;
      the participants. In the BIOLOGIC study we include both lean subjects and obese subjects as&#xD;
      we expect differences in postprandial responses related to differences in chylomicron&#xD;
      production and LPS levels. Therefore it is important to explore these biomarkers in both&#xD;
      target groups. This study can therefore be regarded as group-related, non-therapeutic&#xD;
      research.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 8, 2021</start_date>
  <completion_date type="Actual">July 27, 2021</completion_date>
  <primary_completion_date type="Actual">July 27, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>LPS_B1</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum levels LPS venous blood samples under fasting conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ApoB48_B1</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum levels ApoB48 venous blood samples under fasting conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS_B2</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum levels LPS finger prick blood under fasting conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ApoB48_B2</measure>
    <time_frame>Baseline</time_frame>
    <description>Serum levels ApoB48finger prick blood under fasting conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS1-1</measure>
    <time_frame>1 hour post ingestion</time_frame>
    <description>Serum levels LPS venous blood samples after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ApoB48_1-1</measure>
    <time_frame>1 hour post ingestion</time_frame>
    <description>Serum levels ApoB48 venous blood samples after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS1-2</measure>
    <time_frame>1 hour post ingestion</time_frame>
    <description>Serum levels LPS finger prick blood after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ApoB48_1-2</measure>
    <time_frame>1 hour post ingestion</time_frame>
    <description>Serum levels ApoB48 finger prick blood after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS2-1</measure>
    <time_frame>2 hours post ingestion</time_frame>
    <description>Serum levels LPS venous blood samples after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ApoB48_2-1</measure>
    <time_frame>2 hours post ingestion</time_frame>
    <description>Serum levels ApoB48 venous blood samples after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS2-2</measure>
    <time_frame>2 hours post ingestion</time_frame>
    <description>Serum levels LPS finger prick blood after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ApoB48_2-2</measure>
    <time_frame>2 hours post ingestion</time_frame>
    <description>Serum levels ApoB48 finger prick blood after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS4-1</measure>
    <time_frame>4 hours post ingestion</time_frame>
    <description>Serum levels LPS venous blood samples after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ApoB48_4-1</measure>
    <time_frame>4 hours post ingestion</time_frame>
    <description>Serum levels ApoB48 venous blood samples after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS4-2</measure>
    <time_frame>4 hours post ingestion</time_frame>
    <description>Serum levels LPS finger prick blood after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ApoB48_4-2</measure>
    <time_frame>4 hours post ingestion</time_frame>
    <description>Serum levels ApoB48 finger prick blood after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS6-1</measure>
    <time_frame>6 hours post ingestion</time_frame>
    <description>Serum levels LPS venous blood samples after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ApoB48_6-1</measure>
    <time_frame>6 hours post ingestion</time_frame>
    <description>Serum levels ApoB48 venous blood samples after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LPS6-2</measure>
    <time_frame>6 hours post ingestion</time_frame>
    <description>Serum levels LPS finger prick blood after high-fat shake intake</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ApoB48_6-2</measure>
    <time_frame>6 hours post ingestion</time_frame>
    <description>Serum levels ApoB48 finger prick blood after high-fat shake intake</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LBP_B</measure>
    <time_frame>Baseline</time_frame>
    <description>Plasma LBP levels in venous blood samples collected under fasting conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBP_1</measure>
    <time_frame>1 hour post ingestion</time_frame>
    <description>Plasma LBP levels in venous blood samples after high-fat shake intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBP_2</measure>
    <time_frame>2 hours post ingestion</time_frame>
    <description>Plasma LBP levels in venous blood samples after high-fat shake intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBP_4</measure>
    <time_frame>4 hours post ingestion</time_frame>
    <description>Plasma LBP levels in venous blood samples after high-fat shake intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LBP_6</measure>
    <time_frame>6 hours post ingestion</time_frame>
    <description>Plasma LBP levels in venous blood samples after high-fat shake intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCD14_B</measure>
    <time_frame>Baseline</time_frame>
    <description>Plasma sCD14 levels in venous blood samples collected under fasting conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCD14_1</measure>
    <time_frame>1 hour post ingestion</time_frame>
    <description>Plasma sCD14 levels in venous blood samples after high-fat shake intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCD14_2</measure>
    <time_frame>2 hours post ingestion</time_frame>
    <description>Plasma sCD14 levels in venous blood samples after high-fat shake intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCD14_4</measure>
    <time_frame>4 hours post ingestion</time_frame>
    <description>Plasma sCD14 levels in venous blood samples after high-fat shake intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sCD14_6</measure>
    <time_frame>6 hours post ingestion</time_frame>
    <description>Plasma sCD14 levels in venous blood samples after high-fat shake intake</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Biomarker</condition>
  <arm_group>
    <arm_group_label>Lean subjects</arm_group_label>
    <description>BMI 18.5-22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese subjects</arm_group_label>
    <description>BMI&gt;30</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood samples and blood collected via finger pricks&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In the current study we aim to include 5 lean subjects and 5 obese subjects. We expect&#xD;
        different biomarker responses to a high fat load between these groups of subjects and&#xD;
        therefore it is relevant to explore whether the proposed biomarkers are valid in both sub&#xD;
        population groups.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-70 years&#xD;
&#xD;
          -  Living in the surroundings of Wageningen (max. 25 km)&#xD;
&#xD;
          -  Stable body weight for past 6 months&#xD;
&#xD;
          -  Suitable veins for insertion of cannula&#xD;
&#xD;
          -  BMI 18.5-22 kg/m2 (lean subjects)&#xD;
&#xD;
          -  BMI â‰¥ 30 kg/m2 (obese subjects)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of cholesterol-lowering medication (e.g. statins)&#xD;
&#xD;
          -  Use of diabetes medication (e.g. insulin, metformin)&#xD;
&#xD;
          -  Use of antibiotics or anti-inflammatory medication (e.g. NSAIDS such as ibuprofen)&#xD;
&#xD;
          -  Known allergy for any of the food components used in the study (milk, cream, sugars)&#xD;
&#xD;
          -  Blood clotting disorders&#xD;
&#xD;
          -  Current smokers&#xD;
&#xD;
          -  Alcohol consumption of &gt; 21 units per week&#xD;
&#xD;
          -  Participation in another clinical trial at the same time&#xD;
&#xD;
          -  Being an employee of Wageningen Food &amp; Biobased Research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Stichting Wageningen Research</name>
      <address>
        <city>Wageningen</city>
        <state>Gelderland</state>
        <zip>6708 WG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wageningen University and Research</investigator_affiliation>
    <investigator_full_name>Diederik Esser</investigator_full_name>
    <investigator_title>Clinical Trial Coordinator</investigator_title>
  </responsible_party>
  <keyword>LPS</keyword>
  <keyword>biomarker</keyword>
  <keyword>finger prick test</keyword>
  <keyword>postprandial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

